Collateral for a security interest recorded Apr 27, 2026 (Citibank, N.A.).
Term ends no later than May 16, 2027 · Low confidence
20-year base term ends May 16, 2027
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Held by BPCR Limited Partnership
Filed Oct 31, 2016 as application 15/338,923 · Granted Jun 5, 2018
Base term, 20 years from filing
Today
2007
2027
Clock starts
May 16, 2007
May 16, 2007
Ends no later than
May 16, 2027
May 16, 2027
Granted
Jun 5, 2018
Jun 5, 2018
base term
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. 2 of 2 maintenance fees are paid so far. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 16, 2007, when application 11/749,512, the earliest non-provisional in its chain, was filed (this one was filed Oct 31, 2016); a parent in its chain could not be resolved (the next row) | May 16, 2027 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than May 16, 2027 | Low confidence |
This family
| US 7,851,143 | In force May 2027 | May 2027 |
| Application 12/966,904 | Abandoned not computed | not computed |
| US 9,000,011 | In force May 2027 | May 2027 |
| US 9,480,682 | In force May 2027 | May 2027 |
| US 9,987,263 | this patent no later than May 2027 | no later than May 2027 |
| US 10,406,143 | In force (reinstated) May 2027 | May 2027 |
| US 10,383,864 | In force May 2027 | May 2027 |
| US 11,241,422 | In force May 2027 | May 2027 |
8 of 9 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 6, 2018 Reel 46799, frame 464 | Lockhart, David J.; Castelli, Jeff | Amicus Therapeutics, Inc. | Assignment of Assignor's Interest |
| Sep 28, 2018 Reel 47004, frame 208 | Amicus Therapeutics, Inc. | Biopharma Credit PLC | Security Interest |
| May 11, 2020 Reel 52625, frame 916 | Amicus Therapeutics, Inc. | Biopharma Credit PLC | Security Interest |
| May 21, 2020 Reel 52741, frame 173 | Biopharma Credit PLC | BPCR Limited Partnership | Omnibus Confirmation of Assignment Agreement |
| Jul 30, 2020 Reel 53360, frame 659 | BPCR Limited Partnership | Amicus Therapeutics, Inc. | Release of Security Interest |
| Jul 30, 2020 Reel 53365, frame 342 | Amicus Therapeutics, Inc. | Hayfin Services LLP, as Agent | Security Interest |
| Oct 6, 2023 Reel 65177, frame 196 | Amicus Therapeutics, Inc. | Wilmington Trust, National Association | Security Interest |
| Oct 6, 2023 Reel 65164, frame 945 | Hayfin Services LLP | Amicus Therapeutics, Inc. | Release of Security Interest |
| Apr 27, 2026 Reel 75493, frame 968 | Biomarin Pharmaceutical Inc.; Amicus Therapeutics, Inc. | Citibank, N.A., as Collateral Agent | Security Interest |
| Apr 27, 2026 Reel 75494, frame 30 | Wilmington Trust, National Association | Amicus Therapeutics, Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
May 2027
Term ends no later than May 16, 2027. No further fees fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than May 16, 2027. We will not guess the cap.
Citations
48
later US patents cite this one
That is top 5% of utility patents granted in 2018 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.